Please login to the form below

Not currently logged in
Email:
Password:

Biomunex appoints scientific and strategic advisors

Dr Sebastian Amigorena and Dr Dragan Grabulovski

Biomunex Dr Sebastian AmigorenaParis, France-based immuno-oncology specialist Biomunex Pharmaceuticals has appointed Dr Sebastian Amigorena and Dr Dragan Grabulovski as key scientific advisor and key strategic advisor, respectively.

Dr Amigorena (pictured right) is currently a research director at Le Centre National de la Recherché Scientifique (CNRS) and is director of the Inserm Immunity and Cancer Unit at the Institut Curie in Paris.

In his role as scientific advisory, he will help the company to leverage its 'Plug-and-Play' antibody platform for the development of Biomunex's immunotherapeutics pipeline.

Biomunex Dr Dragan GrabulovskiMeanwhile, Dr Grabulovski (pictured left) is a pharmaceutical biotechnology advisor at Grabulovski Consulting Services, having previously served as chief scientific officer of Covagen, which he co-founded.

Prior to Covagen's sales to Johnson & Johnson in 2014, Dr Grabulovski was responsible for the Swiss biotech's research and development strategy, including its Fynomer technology.

Dr Pierre-Emmanuel Gerard, chief executive officer at Biomunex, said: “We are very pleased to welcome Dr Amigorena and Dr Grabulovski as key advisors.

“As international key opinion leaders they will play an instrumental role as we advance our first oncology programmes into pre-clinical and clinical development."

22nd December 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics